| ¿µ¹® | parenteral administration of drugs | ÇÑ±Û | ºñ°æ±¸Àû ¾àǰÅõ¿© |
|---|---|---|---|
| ¼³¸í | ÀÔÀ» ÅëÇÏÁö ¾Ê´Â ´Ù¾çÇÑ ¾àǰÅõ¿© ¹æ¹ýÀ» ¸»ÇÔ. ÁÖ»ç±â¸¦ ÀÌ¿ëÇÑ´Ù. 1)ÇÇÇÏÁÖ»ç: subcutaneous injection-ÇǺΠ¹ØÀ¸·Î ÁÖ»çÇÏ´Â °Í. ´ë°³ ÆÈÀÇ Áß°£ºÎ¿¡ ÁÖ»çÇÑ´Ù. 2)ÁøÇdz»ÁÖ»ç: intradermal injection-¾ã°Ô Âñ·¯¼ ÁøÇdz»¿¡ ÁÖ»çÇÑ´Ù. ÁÖ·Î ¾Ë·¯Áö ȯÀÚÀÇ Ç׿ø°Ë»ç¿¡ ÀÌ¿ëÇÑ´Ù. 3)±ÙÀ°³»ÁÖ»ç: intramuscular injection-À§ÆÈÀ̳ª, ȤÀº ¾ûµ¢ÀÌ ºÎÀ§¿¡ ÁÖ»çÇÑ´Ù. À̰ÍÀº ÁÖ·Î ÇǺο¡ ÀÚ±ØÀÌ ½ÉÇÑ ¾àÁ¦³ª ȤÀº õõÈ÷ ÀÛ¿ëÇÏ´Â ¾àÁ¦¸¦ ¸¹ÀÌ ÁÖ»çÇÒ ¶§ »ç¿ëÇÑ´Ù. 4)Ç÷°üÁÖ»ç: intravenous(IV) injection-Á¤¸ÆÀ» ÅëÇØ ÁÖ»çÇÑ´Ù. ¾î´À Á¤¸ÆÀ̳ª °¡´ÉÇÏÁö¸¸, ´ë°³ ÆÈ¶ÒÀ̳ª ¹ß µîÀÇ Á¤¸ÆÀ» ÀÌ¿ëÇÑ´Ù. ºü¸¥ Ä¡·áÈ¿°ú¸¦ º¸±â À§ÇØ »ç¿ëÇÑ´Ù. À̶§ ÇǺο¡ ÀÚ±ØÀ» ÁÖ´Â ¾àÁ¦À̸é, »õÁö ¾Êµµ·Ï Á¶½ÉÇØ¾ß ÇÑ´Ù. 5) ¼ö¸·°³»ÁÖ»ç: intrathecal injection-µÎ°³³ª ô¼ö°³»¿¡ ÁÖ»çÇÒ ¶§ ÀÌ¿ëÇÑ´Ù. 6)°³»ÁÖ»ç: intracavitary injection-°ø°£À¸·Î µÈ ºÎÀ§¿¡ ÁÖ»çÇÑ´Ù. ¿¹¸¦ µé¾î º¹ºÎ°ø°£À̳ª Èä°³»¿¡ ÁÖ»çÇÏ¿© »ç¿ëÇÑ´Ù. |
||
| ¿µ¹® | antihypertensive drug | ÇÑ±Û | °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦ |
|---|---|---|---|
| ¼³¸í | °íÇ÷¾ÐÀÇ Ä¡·á¿¡ »ç¿ëÇÏ¸ç ³ôÀº Ç÷¾ÐÀ» ³·Ãß´Â ¾à¹°À» ¸»ÇÑ´Ù. °íÇ÷¾Ð¾à¿¡´Â Ç÷°üÆòȰ±Ù¿¡ Á÷Á¢ ÀÛ¿ëÇÏ¿© À̿ϽÃŰ´Â Ç÷°üÈ®ÀåÁ¦(È÷µå¶ó¶óÁø), ±³°¨½Å°æÀÇ È°µ¿À» ¾îµð¼±°¡ Â÷´ÜÇÏ´Â ¾à¹°(·¹¼¼¸£ÇÉ, ¸ÞÆ¿µµÆÄ, ÇÁ·ÎÇÁ¶ó³ë·Ñ), ÀÌ´¢Á¦(ÇÁ·Î¼¼¹Ìµå, ¿¡Å¸Å©¸°»ê)ÀÌ »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | antimalarial drug | ÇÑ±Û | ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦ |
|---|---|---|---|
| ¼³¸í | ¸»¶ó¸®¾Æ Ä¡·á¿¡ ¾²´Â ¾à. Ű´Ï³×, Ŭ·Î·ÎÄý, ÇÁ¸®¸¶Äý µûÀ§°¡ ÀÖ´Ù. ¸»¶ó¸®¾Æ ¿øÃæÀÇ ¹ßÀ°Áֱ⿡ ´ëÀÀÇØ¼ ¾à¹°ÀÌ ÀÖÀ¸³ª ´ëºÎºÐÀº º´¿ë¿ä¹ý¿¡ µû¶ó¼ ¸»¶ó¸®¾Æ Ä¡·á¸¦ ÇÑ´Ù. ¸ð±â¿¡ ÀÇÇÑ Æ÷ÀÚü°¨¿°¿¡ ´ëÇÑ Çׯ÷ÀÚü ¾àÀº µ¶¼º µîÀÇ ¹®Á¦°¡ ÀÖ¾î¼ ¾ÆÁ÷ ¾ø´Ù. ÀûÇ÷±¸³»¿¡¼ÀÇ È¯»óü, ¹ø½Äü¿¡¸¸ ÀÛ¿ëÇÏ´Â °Í(Ç×¹ø½Äü ¾àÀº Ŭ·Î·ÎÄý, ÇǸ®¸ÞŸ¹Î, Ŭ·Î·Î±¸¾Æ³ªÀ̵å, Ű´Ï³×)Àº ÀûÇ÷±¸ ¿ÜÀÇ ¹ßÀ°Àº ¾ïÁ¦ÇÏÁö ¾ÊÀ¸¹Ç·Î °¨¿°À» ¿ÏÀüÈ÷ ÀúÁöµÇÁö ¾Ê´Â´Ù. ÀûÇ÷±¸³»¿ÜÀÇ ¿øÃæ¿¡ ÀÛ¿ëÇØ ¿ÏÀüÈ÷ °¨¿°À» ¾ïÁ¦ÇÏ´Â °Í(ÆÄ¸¶Å², ÆæÅ¸Å², ÇÁ¸®¸¶Å²), Ç÷ÁßÀÇ »ý½Äü¸¦ Á×ÀÌ´Â °Í(´ëºÎºÐÀÇ Ç׸»¶ó¸®¾ÆÁ¦)Àº ¸ð±â¿¡ ÀÇÇÑ Å¸ÀÎÀ¸·ÎÀÇ Àü¿°¿øÀº ²÷±â´Âµ¥ ȯÀÚÀÚ½ÅÀÇ Áõ»óÀº º¯ÈÇÏÁö ¾Ê´Â´Ù. |
||
| ¿µ¹® | drug | ÇÑ±Û | ¾à, ¾à¹°, ¾àÁ¦ |
|---|---|---|---|
| ¼³¸í | 1. º´, ±âŸ º´Àû »óÅÂÀÇ Áø´Ü, Ä¡·á, ¿¹¹æÀ̳ª °íÅëÀÇ °æ°¨, ¶Ç´Â »ý¸®Àû, º´¸®Àû »óŸ¦ È£Àü½ÃŰ´Â °ÍÀ» ¸ñÀûÀ¸·Î »ç¶÷ ¶Ç´Â µ¿¹°¿¡ Åõ¿©µÇ´Â ÈÇÕ¹°. ¾à¸®Çп¡¼´Â Ä¡·á¾à¸¸ÀÌ ¾Æ´Ï¶ó, »ýü¿¡ ÁÖ¾îÁ³À» ¶§ ¾î¶°ÇÑ ¹ÝÀÀÀ» ³ªÅ¸³»´Â ÈÇй°Áú ¸ðµÎ¸¦ ¾à¹°À̶ó°í ÇÑ´Ù. ÀÛ¿ëÀÌ °ÇÏ°í ¾ÈÀü¼ºÀÌ ³·Àº ¼ø¼·Î µ¶¾à-±Ø¾à-º¸Åë¾àÀ¸·Î ±¸ºÐÇϰí ÀÖ´Ù. ¾à¹°Ä¡·á¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÎÀڷμ, »ýüÂÊ ÀÎÀڷδ °³Ã¼Â÷, ¿¬·É, üÁß µîÀÌ ÀÖ°í, ¾à¹°ÂÊ ÀÎÀڷμ´Â Åõ¿©¹æ¹ý, Åõ¿©·®, º´¿ëµÇ°í ÀÖ´Â ´Ù¸¥ ¾à¹° µîÀÌ ÀÖ´Ù. 2. ¾àÀÇ Àç·á°¡ µÇ´Â ¹°Áú. 3. ¿©·¯ °¡Áö ¾àÀ縦 ¼¯¾î Á¶Á¦ÇÑ ¾à. |
||
| ¿µ¹® | drug resistance | ÇÑ±Û | ¾à¹°³»¼º |
|---|---|---|---|
| ¼³¸í | 1. ÈÇпä¹ýÁ¦³ª Ç×»ý¹°ÁúÀÇ ¾î¶² ÀÏÁ¤ ³óµµ·Î ¼¼±ÕÀ» Á×À̰ųª Áõ½ÄÀúÇØ¸¦ ¹Þ´Â °ÍÀ» ÀÌ ÈÇпä¹ýÁ¦³ª Ç×»ý¹°Áú¿¡ °¨¼ö¼ºÀÌ ÀÖ´Ù°í Çϴµ¥, ÀÌ °¨¼ö¼ºÀÌ ¾ø°Ô µÈ »ýŸ¦ ÀúÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. µû¶ó¼ º¯À̹̻ý¹°ÀÇ ¾àÁ¦¿¡ ´ëÇÑ ÀÚÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. 2. ÀǾàǰÀ» °è¼Ó º¹¿ëÇϸé Á¡Â÷ Áõ·®ÇÏÁö ¾ÊÀ¸¸é È¿·ÂÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¼ºÁú. ÀÌ·¯ÇÑ ¶§¸¦ ¾àÁ¦³»¼ºÀÌ »ý°å´Ù°í ÇÑ´Ù. ¸ðµç ¹Ì»ý¹°Àº °¨¼ö¼ºÀ» °¡Áö´Â ¾à¹°¿¡ ÀÇÇÏ¿© »ç¸êµÇÁö¸¸, ¼Ò¼öÀÇ °ÍÀº »ì¾Æ³²¾Æ ±×°ÍÀÌ ÁøÈµÊÀ¸·Î½á »ç¸êÇÏÁö ¾Ê´Â ¼ö°¡ ÀÖ´Ù. ¶Ç, ÃÖÃÊ¿¡´Â °¨¼ö¼ºÀ» °¡Áö°í ÀÖ´ø ±ÕÀÌ Â÷Â÷ ³»¼º±ÕÀ¸·Î µÇ±âµµ ÇÑ´Ù. ¸¹Àº º´¿ø±ÕÀº °¨¼ö¼ºÀÌ ÀÖ´Â ÀǾàǰ¿¡ ´ëÇÏ¿© ³»¼ºÀÌ »ý±ä´Ù. °¡Àå °íµµÀÇ ³»¼º±ÕÀÌ »ý±â±â ½¬¿î °ÍÀº ½ºÆ®·¾Å丶À̽ÅÀε¥ °áÇÙ±Õ°ú ±×¶÷À½¼º±Õ¿¡ ´ëÇÏ¿© ½±°Ô ³»¼ºÀÌ »ý±ä´Ù. Æä´Ï½Ç¸°À̳ª Åׯ®¶ó½ÃŬ¸°(¾ÆÅ©·Î¸¶À̽Å) µîÀÇ Ç×»ý¹°Áúµµ ³»¼ºÀÌ »ý±â±â ½¬¿ì¹Ç·Î, »ç¿ëÇÒ ¶§´Â ÀûÀÀÀ» Àß È®ÀÎÇÏ¿© Çʿ䷮À» Á¤ÇÏ°í ¿¬¿ëÀ» ÇÇÇÑ´Ù. °°Àº È¿°ú°¡ ÀÖ´Â ´Ù¸¥ Á¾·ùÀÇ ¾àÁ¦¸¦ ¼Ò·®¾¿ 2, 3Á¾ º´¿ëÇÏ¸é ³»¼ºÀÇ ¹ß»ýÀÌ Å©°Ô ¾ïÁ¦µÈ´Ù´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ´Ù. °áÇÙ¾àÀ¸·Î¼ ½ºÆ®·¾Å丶À̽Űú ÆÄ½º, ¶Ç´Â À̼ҴϾÆÁöµå¸¦ º´¿ëÇÏ´Â °Í µîÀÌ ±× ¿¹ÀÌ´Ù. |
||
| APA | action potential amplitude; aldosterone-producing adenoma; Ambulatory Pediatric Association; America... |
|---|---|
| AAP | air at atmospheric pressure; American Academy of Pediatrics; American Academy of Pedodontics; Americ... |
| IPA | immunoperoxidase assay; incontinentia pigmenti achromians; independent physician or practice associa... |
| DA | dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis... |
| JAMA | Journal of the American Medical Association |
| JAMA | Journal of the American Medical Association |
|---|---|
| PDA | Parenteral drug abusers |
| NEJM | New England Journal of Medicine |
| HPN | Home Parenteral Nutrition |
| IDPN | Intradialytic parenteral nutrition |
| journal article | The predominant publication type for articles and other items indexed for nlm databases. (12 Dec 1998) |
|---|---|
| drug-drug interaction | The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity. (09 Oct 1997) |
| parenteral | <pharmacology> Not through the alimentary canal but rather by injection through some other route, as subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intrasternal, intravenous, etc. Origin: Gr. Enteron = intestine (18 Nov 1997) |
| parenteral absorption | Absorption by any route other than the alimentary tract. (05 Mar 2000) |
| parenteral nutrition | <gastroenterology, pharmacology> A method of delivering nutrition or other substances directly into a vein. Fluids given usually include salt (saline), glucose, amino acids, electrolytes, vitamins and medications. (16 Dec 1997) |
| parenteral nutrition, home | The at-home administering of nutrients for assimilation and utilization by a patient who cannot maintain adequate nutrition by enteral feeding alone. Nutrients are administered via a route other than the alimentary canal (e.g., intravenously, subcutaneously). (12 Dec 1998) |
| parenteral nutrition, home total | The at-home administering of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously or by some other non-alimentary route. (12 Dec 1998) |
| parenteral nutrition, total | The delivery of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously, or by some other non-alimentary route. The basic components of tpn solutions are protein hydrolysates or free amino acid mixtures, monosaccharides, and electrolytes. Components are selected for their ability to reverse catabolism, promote anabolism, and build structural proteins. (12 Dec 1998) |
| parenteral therapy | Therapy introduced usually by a needle through some other route than the alimentary canal. (05 Mar 2000) |
| infusions, parenteral | The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. (12 Dec 1998) |
| total parenteral nutrition | <pharmacology> Intravenous feeding that provides patients with all essential nutrients when they are unable to feed themselves. Acronym: TPN (12 Jan 1998) |
| american dental association | Professional society representing the field of dentistry. (12 Dec 1998) |
| american heart association | A voluntary organization concerned with the prevention and treatment of heart and vascular diseases. (12 Dec 1998) |
| american hospital association | A professional society in the united states whose membership is composed of hospitals. (12 Dec 1998) |
| american medical association | Professional society representing the field of medicine. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|